ArticleTechniques in coloproctology2026
Initial experience in colorectal robotic surgery in a university hospital: the first 100 consecutive cases using Hugo™ RAS platform.
Article in Techniques in coloproctology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hugo RAS Versus Da Vinci in Colorectal Surgery: A Systematic Review and Outcome Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Hugo™ RAS platform (Medtronic
methodsWe retrospectively analyzed 100 consecutive adult patients (median age 68 years; 51% male) undergoing elective colorectal resection using Hugo™ RAS between April 2023 and December 2024. Surgical indications included malignancy (78%), benign neoplasia, and inflammatory disease. Primary outcomes included operative time, blood loss, conversion rate, oncologic adequacy, complications (Clavien-Dindo classification), and length of stay. Learning curves were assessed via CUSUM analysis.
resultsMedian operative time was 180 min (IQR 147.5-240.0), with blood loss of 50 mL (IQR 50-100). No conversions occurred. R0 resection was achieved in 93% of applicable cases, with median lymph node harvest of 20. Overall morbidity was 28%, including 5% major complications (Clavien-Dindo ≥ IIIb) and zero grade IV/V events. Median stay was 6 days. Male patients had significantly higher complication rates (39.2% vs 16.3%, p = 0.011). Comparing first versus last 50 cases, complications decreased from 34% to 22% (p = 0.181), while major complications remained stable. CUSUM analysis revealed stabilization after approximately 50 cases.
conclusionsThe Hugo™ RAS platform enabled safe and effective colorectal surgery with zero conversions and oncologic outcomes meeting established benchmarks. The learning curve stabilized at 50 cases with progressive reduction in minor complications. These results support Hugo™ RAS as a valuable addition to minimally invasive colorectal surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.